Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603234 | 0.93 | MAP4K4 (0.44) | CYP17A1MAPKAPK2MAP4K4NAMPTPDGFRA | |
| SCHEMBL13603238 | 0.90 | CYP17A1 (0.42) | CYP17A1MAPKAPK2MAP4K4NAMPTPDGFRA | |
| SCHEMBL3757588 | 0.87 | MAP4K4 (0.47) | CYP17A1MAPKAPK2MAP4K4NAMPTPDGFRA | |
| SCHEMBL12616800 | 0.87 | EGFR (0.41) | CYP17A1MAP4K4NAMPTPDGFRAKDR | |
| SCHEMBL13603233 | 0.85 | CYP17A1 (0.46) | CYP17A1MAP4K4NAMPTPDGFRAKIT | |
| SCHEMBL4454565 | 0.84 | PDGFRA (0.43) | PDGFRAKITMETKDRMAPK14 | |
| SCHEMBL2316612 | 0.83 | KDR (0.47) | CYP17A1PDGFRAKITMETKDR | |
| SCHEMBL4466297 | 0.83 | PRMT1 (0.49) | CYP17A1MAPKAPK2NAMPTPDGFRAKIT | |
| SCHEMBL13603250 | 0.81 | MAP4K4 (0.47) | CYP17A1MAPKAPK2MAP4K4NAMPTPDGFRA | |
| SCHEMBL31600006 | 0.78 | ATR (0.43) | CYP17A1MAPKAPK2MAP4K4NAMPTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812433-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | NR2E1, NR0B1, BRAF | CYP17A1 2508/4885MAPKAPK2 304/4885MAP4K4 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.